Repligen CEO to Present at Upcoming Investor Conferences

  Repligen CEO to Present at Upcoming Investor Conferences

- Stephens Fall Investment Conference & Piper Jaffray Healthcare Conference -

Piper Jaffray Technology, Media & Telecommunications Conference 2012

Business Wire

WALTHAM, Mass. -- November 07, 2012

Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy,
Ph.D., President and Chief Executive Officer, will be presenting at two
investor conferences in November. Dr. Herlihy will first participate in the
Stephens Fall Investment Conference on November 14, and will later present at
the Piper Jaffray 24^th Annual Healthcare Conference on November 27. Both
conferences will take place at The New York Palace Hotel. At each, Dr. Herlihy
will provide a corporate update and address questions from the audience.

Repligen’s presentation at the Piper Jaffray Annual Healthcare Conference will
be webcast and made available live through the Investors section of Company’s
website at www.repligen.com. This presentation is currently scheduled to begin
on Tuesday, November 27 at 8:50 a.m. EST. To access the live webcast, please
log on approximately 15 minutes prior to the scheduled start time. The webcast
will also be archived for a period of time on the Company’s website.

About Repligen Corporation

Repligen Corporation is a life sciences company focused on the development,
production and commercialization of high-value consumable products used in the
process of manufacturing biological drugs. Our bioprocessing products are sold
to major life sciences and biopharmaceutical companies worldwide. We are a
leading manufacturer of Protein A, a critical reagent used during the
production of monoclonal antibody therapeutics. We also supply several growth
factor products used to increase cell culture productivity during
fermentation. In the burgeoning area of disposable biomanufacturing
technologies, we have developed and market a series of OPUS^®(Open Platform
User Specified) pre-packed chromatography columns for use in clinical-stage
and/or niche biologics manufacturing. In addition to our core bioprocessing
business, we have a portfolio of clinical-stage partnering assets, including
our pancreatic imaging agent in Phase 3 development and two central nervous
system orphan drug candidates. Repligen’s corporate headquarters are located
in Waltham, MA, USA; we have an additional manufacturing facility in Lund,
Sweden. For more information, please visit our website at www.repligen.com.

This press release may contain forward-looking statements within the meaning
of the federal securities laws. Investors are cautioned that statements in
this press release which are not strictly historical statements including,
without limitation, statements identified by words like “believe,” “expect,”
“may,” “will,” “should,” “seek,” or “could” and similar expressions,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, risks discussed from
time to time in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update forward-looking statements,
except as required by law.

Contact:

Repligen Corporation
Sondra S. Newman, 781-419-1881
Director Investor Relations
snewman@repligen.com
 
Press spacebar to pause and continue. Press esc to stop.